Home > Drugs A – Z > Ritonavir (By mouth)

Ritonavir (By mouth)

Treats HIV infection. HIV causes AIDS. This medicine does not cure HIV or AIDS, but combinations of drugs may slow the progress of the disease.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Ritonavir is used together with other medicines for the treatment of the infection caused by the human immunodeficiency virus (HIV). HIV is the virus that causes acquired immune deficiency syndrome (AIDS). Ritonavir will not cure or prevent HIV infection or AIDS. It helps keep HIV from reproducing and appears to slow down the destruction of the immune system. This may help delay problems that are… Read more
Brand names include
Norvir, ritonavir
Drug classes About this
Antiretroviral Agent
Combinations including this drug

What works? Research summarized

Evidence reviews

Ombitasvir / Paritaprevir / Ritonavir -- Benefit Assessment According to §35a Social Code Book V [Internet]

The aim of the present report is to assess the added benefit of the fixed-dose combination OBV / PTV / R in comparison with dual therapy of peginterferon and ribavirin (PEG + RBV) or triple therapy of telaprevir, peginterferon and ribavirin (TVR + PEG + RBV) as appropriate comparator therapy (ACT) in patients with chronic hepatitis C (CHC) genotype 1 and 4.

Dasabuvir and Ombitasvir / Paritaprevir / Ritonavir (Addendum to Commissions A15-03 and A15-04) [Internet]

On 11 June 2015, the Federal Joint Committee (G-BA) commissioned the Institute for Quality and Efficiency in Health Care (IQWiG) to conduct a supplementary assessment for the commissions A15-03 (Dasabuvir – Benefit assessment according to §35a Social Code Book V) and A15-04 (Ombitasvir / paritaprevir / ritonavir – Benefit assessment according to §35a Social Code Book V).

Holkira (Ombitasvir/Paritaprevir/ Ritonavir with Dasabuvir) and Harvoni (Ledipasvir/Sofosbuvir) for Chronic Hepatitis C: A Review of the Clinical Evidence [Internet]

The treatment of chronic hepatitis C (CHC) using the all oral, interferon-free regimen has potential advantages compared with interferon-based regimens. This report reviews the evidence of clinical effectiveness and safety of Harvoni and Holkira Pak for the management of CHC genotype 1, which may assist in healthcare funding decision-making in the context of the publicly funded healthcare system. Due to the complex generic names, the trade names of these therapies will be used in the review for clarity.

See all (61)

Summaries for consumers

Fixed combination of ombitasvir / paritaprevir / ritonavir (Viekirax) for hepatitis C (genotype 1a) with previous treatment and without liver cirrhosis

In early 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of the fixed combination ombitasvir / paritaprevir / ritonavir for people with hepatitis C compared with standard therapies. The following results apply to people with a chronic HCV infection (genotype 1a) without liver cirrhosis who have previously been treated unsuccessfully. The manufacturer provided one relevant study. One group of participants (19 people) took the fixed combination ombitasvir / paritaprevir / ritonavir as part of a triple therapy together with dasabuvir and ribavirin. Another group (7 people) had standard therapy with peginterferon, ribavirin, and telaprevir. The results of this study are described below.

Fixed combination of ombitasvir / paritaprevir / ritonavir (Viekirax) for hepatitis C (genotype 1a) without previous treatment and without liver cirrhosis

In early 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of the fixed combination ombitasvir / paritaprevir / ritonavir in people with hepatitis C compared with standard therapies. The following results apply to people with a chronic HCV infection (genotype 1a) without cirrhosis who have not had any previous treatment. The manufacturer provided one relevant study. One group of participants (69 people) took the fixed combination ombitasvir / paritaprevir / ritonavir as part of a triple therapy together with dasabuvir and ribavirin. Another group (34 people) had a standard therapy with peginterferon, ribavirin, and telaprevir. The results are described below.

Fixed combination of ombitasvir / paritaprevir / ritonavir (Viekirax) for hepatitis C (genotype 1b) without previous treatment and without liver cirrhosis

In early 2015, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into the advantages and disadvantages of the fixed combination ombitasvir / paritaprevir / ritonavir for people with hepatitis C compared with standard therapies. The following results apply to people with a chronic HCV infection (genotype 1b) without cirrhosis who have not had any previous treatment. The manufacturer provided one relevant study. One group of participants (83 people) took the fixed combination ombitasvir / paritaprevir / ritonavir as part of a dual therapy together with dasabuvir. Another group (41 people) had a standard therapy with peginterferon, ribavirin, and telaprevir. The results of this study are described below.

See all (19)

PubMed Health Blog...

read all...